Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham Paxil

Executive Summary

Paroxetine sNDA submitted July 21 for the treatment of post-traumatic stress disorder

You may also be interested in...



Paxil Generalized Anxiety Relapse Prevention Data To Be Presented At APA

GlaxoSmithKline will present results from a 32-week study of Paxil in relapse prevention of generalized anxiety disorder at the American Psychiatric Association annual meeting in New Orleans May 5-10.

Paxil Generalized Anxiety Relapse Prevention Data To Be Presented At APA

GlaxoSmithKline will present results from a 32-week study of Paxil in relapse prevention of generalized anxiety disorder at the American Psychiatric Association annual meeting in New Orleans May 5-10.

SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate

SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.

Related Content

UsernamePublicRestriction

Register

PS036446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel